A large proportion of late-stage breast cancers that have spread to other parts of the body (metastatic breast cancers) are characterized by overexpression of the protein Mdm2. Lindsey Mayo and ...

Almost half of patients with advanced solid tumors or lymphomas experienced disease control with a drug that reactivates the TP53 tumor suppressor, a first-in-human study showed. Overall, the oral ...

The p53–Mdm2 system is key to tumor suppression. We have recently reported that p53 as well as Mdm2 are capable of supporting DNA replication fork progression. On the other hand, we found that Mdm2 is ...

Overexpression of MDM2 is described in many human cancers, including breast carcinoma. 1, 3, 8 Overexpression of MDM2 protein correlates with high grade and was found to be an independent negative ...

Outside of breast cancer, cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors have not been as successful as tumors develop resistance. New research shows that a murine double minute (MDM2) ...

Overexpression of c-met as a Prognostic Indicator for Transitional Cell Carcinoma of the Urinary Bladder: A Comparison With p53 Nuclear Accumulation PURPOSE: Testicular germ cell tumors (TGCTs) of ...

The oncoproteins MDM2 and MDMX negatively regulate the activity and stability of the tumor suppressor protein p53—a cellular process initiated by MDM2 and/or MDMX binding to the Nterminal ...

Over the past two decades, the idea of targeting transcription factors to combat malignancies has turned into a clinical reality. Targeting oncogenes and their interactive partners is an effective ...

WATERTOWN, Mass., June 01, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using ...

New findings show that a wider study is needed for MDM2 inhibitors in treating patients with AML. Studying MDM2 inhibitors using Venetoclax (Venclexta) has led to unique responses in patients with ...

A study has identified a possible second-line treatment for melanoma patients. A study from Vanderbilt-Ingram Cancer Center and the Department of Veterans Affairs led by Anna Vilgelm, MD, PhD, and Ann ...